PMV Pharmaceuticals (PMVP)
NASDAQ:PMVP
US Market

PMV Pharmaceuticals (PMVP) Stock Forecast & Price Target

49 Followers
See the Price Targets and Ratings of:

Analyst Rating Consensus

Moderate Buy
1Ratings
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
PMV
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PMVP Stock Price Prediction

Average Price Target

$36.00
▲(251.56% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for PMV Pharmaceuticals in the last 3 months. The average price target is $36.00 with a high forecast of $36.00 and a low forecast of $36.00. The average price target represents a 251.56% change from the last price of $10.24.
Highest Price Target$36.00Average Price Target$36.00Lowest Price Target$36.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Oppenheimer
$33.00
Buy
222.27%
Upside
Reiterated
PMV Pharmaceuticals price target raised to $33 from $30 at OppenheimerPMV Pharmaceuticals price target raised to $33 from $30 at Oppenheimer
Evercore ISI
$50.00
Buy
388.28%
Upside
Reiterated
Evercore ISI Thinks PMV Pharmaceuticals' Stock is Going to Recover
Bank of America Securities
$62.00
Buy
505.47%
Upside
Reiterated
PMV Pharmaceuticals (PMVP) PC14586 ASCO Abstract Reinforces Blockbuster Potential, BofA Securities Hosting a Call TodayThe analyst stated "In our view, the abstract could begin to derisk the program, and while investor expectations appear low, we think early signs of efficacy are likely to support continued development. We think PC14586 could have blockbuster potential with the ability to reach about 1.8% of all p53 mutant cancers by targeting the Y220C mutation (peak sales $1.5B), and with the unique mechanism of action and a safety profile unlikely to overlap with other treatments, we think it could find a place in treatment paradigms across indications."
Guggenheim
$30.00
Buy
192.97%
Upside
Reiterated
PMV Pharmaceuticals Inc. (PMVP) PT Lowered to $30 at GuggenheimGuggenheim analyst Charles Zhu lowered the price target on PMV Pharmaceuticals Inc. (NASDAQ: PMVP) to $30.00 (from $46.00) while maintaining a Buy rating.
Goldman Sachs Analyst forecast on PMVP
Unknown Analyst
Not Ranked
Goldman Sachs
$25.00
Buy
144.14%
Upside
Reiterated
Stocks with the Highest Top Analyst Consensus in the Services Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Services sector that are highly recommended by Top Performing Analysts.

PMVP Financial Forecast

PMVP Earnings Forecast
Next quarter’s earnings estimate for PMVP is -$0.44 with a range of -$0.45 to -$0.41. The previous quarter’s EPS was -$0.40. PMVP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.91% of the time in the same period. In the last calendar year PMVP has Underperformed its overall industry.
Next quarter’s earnings estimate for PMVP is -$0.44 with a range of -$0.45 to -$0.41. The previous quarter’s EPS was -$0.40. PMVP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.91% of the time in the same period. In the last calendar year PMVP has Underperformed its overall industry.
No data currently available
PMVP Sales Forecast
Next quarter’s sales forecast for PMVP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PMVP beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 65.13% of the time in the same period. In the last calendar year PMVP has Underperformed its overall industry.
Next quarter’s sales forecast for PMVP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PMVP beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 65.13% of the time in the same period. In the last calendar year PMVP has Underperformed its overall industry.
PMVP Analyst Recommendation Trends
In the current month, PMVP has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PMVP average analyst price target in the past 3 months is $36.00
In the current month, PMVP has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PMVP average analyst price target in the past 3 months is $36.00

PMVP Stock Forecast FAQ

What is PMVP’s average 12-month price target, according to analysts?
Based on analyst ratings, PMV Pharmaceuticals’s 12-month average price target is $36.00.
    What is PMVP’s upside potential, based on the analysts’ average price target?
    PMV Pharmaceuticals has 251.56% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PMVP a Buy, Sell or Hold?
          PMV Pharmaceuticals has a conensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is PMV Pharmaceuticals’s price target?
            The average price target for PMV Pharmaceuticals is $36.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $36.00 ,the lowest forecast is $36.00. The average price target represents 251.56% Increase from the current price of $10.24.
              What do analysts say about PMV Pharmaceuticals?
              PMV Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis